Daniel Cher

Daniel Cher is a board-certified internist with over 15 years of clinical affairs and research experience in a variety of medical device technology companies. His experience includes developing clinical and regulatory strategy, designing and leading clinical trials, directing clinical research, and consulting with a variety of medical device technology companies.

Most recently, he served as VP of Clinical and Regulatory Affairs at Chestnut Medical, an early-stage company developing new minimally invasive therapies for Interventional Neuroradiology. At Chestnut, he lead clinical trials and regulatory affairs for the Pipeline Embolization Device, a novel device for the treatment of large and giant intracranial aneurysms, which received FDA approval in April 2011.

Prior to this, Dr. Cher served as VP of Clinical and Regulatory Affairs at Pulmonx, Inc., and was Medical Director and VP of Clinical Research at Kyphon, Inc., where he directed clinical research.

Educated at Stanford and Yale Universities, Daniel pursued his residency in internal medicine at University of Wisconsin, Madison, and California Pacific Medical Center, in San Francisco. Daniel underwent additional training in general internal medicine and research methods at Stanford University and the Palo Alto VA Hospital.

Daniel left clinical practice in 1999 to lead clinical trials at several San Francisco Bay Area medical device technology companies, including Kyphon. Daniel's focus is on clinical trial design and statistical analysis.

Daniel Cher is the Vice President, Clinical Affairs at SI-BONE, based in United States, North America. With a background in Health Care, Daniel Cher has a rich history of leadership and innovation.Daniel Cher studied unknown unknown at Stanford University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.